Deep learning for H&E-based meningioma molecular classification and outcome prediction: a retrospective cohort study.
AI trained on routine tissue slides could predict brain tumor aggressiveness without expensive genetic testing, bringing precision diagnosis to under-resourced hospitals.
This Lancet Digital Health retrospective cohort study trained and validated a deep learning model on H&E-stained meningioma tissue sections to predict molecular classification (WHO 2021-aligned) and patient outcomes. The approach could democratize meningioma risk stratification by replacing costly molecular sequencing with standard histopathology, immediately actionable in resource-limited settings.
What the study was
- Study design
- Retrospective cohort study
- Population
- Meningioma patients with H&E histopathology slides
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- The Lancet. Digital health
Why it surfaced
Lancet Digital Health retrospective cohort study demonstrating that H&E-based DL can predict meningioma molecular subtype — a NEAR_TERM_IMPLEMENTABLE finding that could eliminate the need for molecular profiling in centers without genomics infrastructure. Directly displaces cost and access barriers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.